• Sucampo Pharmaceuticals Inc., of Bethesda, Md., and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said they filed a supplemental new drug application seeking approval to expand the use of Amitiza (lubiprostone) for treating opioid-induced constipation in patients with chronic, noncancer pain.